Neurol. praxi. 2023;24(3):187-192 | DOI: 10.36290/neu.2023.030

Neurological disorders predominantly involving brainstem and cerebellum

prof. MUDr. Pavel Štourač, Ph.D.
Neurologická klinika Masarykovy univerzity a Fakultní nemocnice Brno

Paraneoplastic, autoimmmune and idiopathic syndromes of brainstem and cerebellum are usually of paraneoplastic origin. The diagnostics are based on the detection of onconeural antibodies, neural cell surface antibodies and imaging methods. The early diagnostics is based on the index of clinical suspicion and enables effective treatment in some cases.

Keywords: idiopathic, autoimmune and paraneoplastic syndromes, cerebellum, brainstem.

Received: April 21, 2023; Revised: May 11, 2023; Accepted: May 11, 2023; Prepublished online: May 11, 2023; Published: June 14, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štourač P. Neurological disorders predominantly involving brainstem and cerebellum. Neurol. praxi. 2023;24(3):187-192. doi: 10.36290/neu.2023.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Afzal S, Recio M, Shamim S. Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. Proc. 2015;28(2):217-220. (PMC free article PMC 4365125). Go to original source... Go to PubMed...
    2. Aly R., Emmady DP. Paraneoplastic cerebellar degeneration Stats Pearl Publishing 2022 ID NBK560638, PMID : 32809473
    3. Armangué T, Sabater L, Torres­‑Vega E, et al. Clinical and Immunological Features of Opsoclonus - Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol. 2016;73(4):417-424. Go to original source... Go to PubMed...
    4. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti - Ma2 associated encephalitis. Brain. 2004;127:1831-1844. Go to original source... Go to PubMed...
    5. Dalmau J, Rosenfeld RM. Paraneoplastic Neurological Syndromes in Abeloff's Clinical Oncology(Sixth Edition), 2020. Go to original source...
    6. De Grandis E, Parodi S, Conte M, et al. Long­‑term follow­‑up of neuroblastoma associated opsoclonus­‑myoclonus - ataxia syndrome. Neuropediatrics. 2009;40(3):103-111. Go to original source... Go to PubMed...
    7. Fanous I. Dillon P. Paraneoplastic neurological complications of breast cancer. Exp Hematol Oncol. 2015;5:29. Go to original source... Go to PubMed...
    8. Graus F, Vogrig A, Muniz­‑Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014. Go to original source... Go to PubMed...
    9. Graus A, Saiz J, Dalmau GAD. Antibodies in neurological disorders - insights and challenges. Nature Reviews. 2020; 16:353-36. Go to original source... Go to PubMed...
    10. Hasegawa S, Matsushige T, Kajimot, M.A. nation wide survey of opsoclonus - myoclonus syndrome in Japanese children. Brain Dev. 2015;37(7):656-660. Go to original source... Go to PubMed...
    11. Hayward K, Jeremy RJ, Jenkins S, et al. Long­‑term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus - ataxia syndrome: relationship to MRI findings and antineuronal antibodies. J Pediatr. 2001;139:552-559. Go to original source... Go to PubMed...
    12. Keime­‑Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti­‑Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide and methylprednisolone. J Neurol Neusurg Psychiatry. 2000;68(4):479-82. Go to original source... Go to PubMed...
    13. Mandel­‑Brehm C, Dubey D, Kryzer TJ, et al. Kelch­­‑like protein 11 antibodies in seminoma associated paraneoplastic encephalitis. N Eng J Med. 2019;381:47-54. Go to original source... Go to PubMed...
    14. Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma. Cancer Lettr. 2005:275-282. Go to original source... Go to PubMed...
    15. Pranzatelli MR, Tate ED, Mc Gee NR. Demographic, clinical and immunological features of 389 children with opsoclonus­‑myoclonus syndrome: a cross sectional study. Fron Neurol. 2017;8:153-158. Go to original source... Go to PubMed...
    16. Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus - myoclonus syndrome etiology ("Tumor" vs. "No Tumor") in a cohort of 356 US children. Pediatr Blood Cancer. 2018;65:e27097. Go to original source... Go to PubMed...
    17. Saiz A, Bruna J, Stourac P, et al. Anti­‑Hu associated brainstem encephalitis. J Neurol Neurosurg Psychiatry. 2009;80: 404-407. Go to original source... Go to PubMed...
    18. Shibasaki H. Electrophysiological studies of myoclonus. Muscle and Nerve. 2005;31:157-174. Go to original source... Go to PubMed...
    19. Shamsili S, Grefkens J, De Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409-18. Go to original source... Go to PubMed...
    20. Tate ED, Allison TJ, Pranzatelli MR,Verhulst SJ. Neuroepidemiological trends in 105 US cases of pediatric opsoclonus- myoclonus syndrome. J Pediatr Oncol Nurs. 2005;22(1):8-19. Go to original source... Go to PubMed...
    21. Wong A. An update on opsoclonus. Curr opin Neurol. 2007;20:25-31. Go to original source... Go to PubMed...
    22. Zoghaib R, Sreij A, Maalouf N, et al. Autoimmune brainstem encephalitis: An illustrative case and a Review of the Literature. J. Clin. Med. 2021;10:2970. https://doi.org/10.3390/jcm10132970. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.